ADVM — Adverum Biotechnologies Share News
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
Brief: Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
Brief: Adverum Biotechnologies Presents Positive End Of Study Results From Optic Trial In Wet AMD Including Two-Year Outcomes Following A Single Intravitreal Injection Of Ixo-Vec (Advm-022)
Adverum Biotechnologies Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Adverum Biotechnologies Presents Anatomical Improvements In Intraretinal And Subretinal Fluid After A Single IVT Injection Of IXO-VEC
Adverum rises as dosing begins in eye therapy study
Brief: Adverum Biotechnologies Announces First Subject Dosed With Ixo-Vec In The Phase 2 Luna Trial For The Treatment Of Wet Age-Related Macular Degeneration
U.S. RESEARCH ROUNDUP- Apple, Dell Technologies, IBM
Adverum Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
Brief: Adverum Biotechnologies Presents Visual Acuity And Central Subfield Thickness Analyses For Ivt Injection Of Advm-022
U.S. RESEARCH ROUNDUP- Brunswick, Hasbro, Seaworld Entertainment
Adverum Biotech to cut jobs; expects to extend cash runway into 2025
Brief: Adverum Biotechnologies Says It Is Reducing Workforce By 78 Employees
Brief: Adverum Biotechnologies Completes IND Amendment And Prepares To Initiate The Phase 2 Luna Trial Of ADVM-022 In Wet AMD
Brief: Adverum Receives Priority Medicines Designation By EMA For ADVM-022 In Wet AMD
U.S. RESEARCH ROUNDUP- Banner, Carmax, Labcorp
Brief: Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression After Single Ivt Injection Of Advm-022
Brief: Adverum Biotechnologies - On June 3, Rupert D'souza Chief Financial Officer Advised Co That He Was Resigning Effective Immediately
Brief: Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy